|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1995-7-25
|
|
pubmed:abstractText |
Back mutations from the TRC-1 beta-lactamase to the TEM-1 enzyme were selected in vitro. The revertant beta-lactamase was obtained from Escherichia coli strain J62.2 carrying plasmid pUK901 which encodes the TRC-1 beta-lactamase. The revertant was obtained after repeated subculture of E. coli J62.2 (pUK901) in amoxycillin 512 mg/L for 5 days. The revertant beta-lactamase had the same pI as TEM-1 (5.4) and had restored inhibition by clavulanic acid (ID50 reduced from 4.2 microM to 0.15 microM). The prevalence of these beta-lactamases in the clinical population may be the result of a two-way flux, with mutations in both forward and backward directions.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-2615
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
429-32
|
|
pubmed:dateRevised |
2009-9-29
|
|
pubmed:meshHeading |
pubmed-meshheading:7791208-Amoxicillin,
pubmed-meshheading:7791208-Anti-Bacterial Agents,
pubmed-meshheading:7791208-Clavulanic Acid,
pubmed-meshheading:7791208-Clavulanic Acids,
pubmed-meshheading:7791208-DNA, Bacterial,
pubmed-meshheading:7791208-Drug Resistance, Microbial,
pubmed-meshheading:7791208-Escherichia coli,
pubmed-meshheading:7791208-Isoelectric Focusing,
pubmed-meshheading:7791208-Mutation,
pubmed-meshheading:7791208-Restriction Mapping,
pubmed-meshheading:7791208-beta-Lactamases
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
|
|
pubmed:affiliation |
Department of Medical Microbiology, Medical School, University of Edinburgh.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
